title: Treatment outcomes stratified by baseline immunological status among young children receiving nonnucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in resource-limited settings.
abstract: A study of 568 children aged <5 years who commenced nonnucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in resource-limited settings revealed good early outcomes. After 12 months of antiretroviral therapy, survival probability was 0.89 (95% confidence interval, 0.86-0.92), with no significant difference among children stratified on the basis of baseline immunological levels; 62% attained a CD4 cell percentage >25%, and 7% continued to have a CD4 cell percentage <15%.
authors.affiliation: AIDS Working Group, Médecins Sans Frontières, Paris, France. daniel.obrien@amsterdam.msf.org
authors.forename: Daniel P
authors.initials: DP
authors.lastname: O'Brien
authors.forename: Delphine
authors.initials: D
authors.lastname: Sauvageot
authors.forename: David
authors.initials: D
authors.lastname: Olson
authors.forename: Myrto
authors.initials: M
authors.lastname: Schaeffer
authors.forename: Pierre
authors.initials: P
authors.lastname: Humblet
authors.forename: Mar
authors.initials: M
authors.lastname: Pudjades
authors.forename: Tom
authors.initials: T
authors.lastname: Ellman
authors.forename: Rony
authors.initials: R
authors.lastname: Zachariah
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Szumilin
authors.forename: Line
authors.initials: L
authors.lastname: Arnould
authors.forename: Tony
authors.initials: T
authors.lastname: Read
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000276:immunology* / Q000401:mortality; D018791:CD4 Lymphocyte Count; D002675:Child, Preschool; D003906:Developing Countries; D004359:Drug Therapy, Combination; D005260:Female; D006295:Health Resources / Q000600:supply & distribution*; D006801:Humans; D007108:Immune Tolerance; D008297:Male; D011336:Probability; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D018894:Reverse Transcriptase Inhibitors